Trimming costs means trimming jobs in healthcare

Healthcare costs have continued to rise above the rate of inflation as more jobs were created in the industry, but as California Healthline reports, trying to cut the former will lead to fewer of the latter.

“The goal of increasing jobs in healthcare is incompatible with the goal of keeping healthcare affordable,” said Harvard University economist Katherine Baicker. “There’s a lot of evidence we can get more bang for our buck in healthcare. We should be aiming for a healthcare system that operates more efficiently and effectively. That might mean better outcomes for patients and fewer jobs.”

Healthcare has accounted for 35 percent of all job growth in the U.S. since 2007, with hiring remaining strong through the Great Recession and then getting a boost as the Affordable Care Act expanded insurance coverage.

That’s not a positive development in the eyes of some economists, as more jobs are far removed from the goal of better patient care. For example, membership in the American Academy of Professional Coders has increased by 10,000 just in the past year for a position that can be described as deciphering “decipher arcane rules to mine money from human ills.”

Read the full article below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.